Table 6.
Results of cost–utility analyses.
| Parameter |
Difference in cost, £ |
Difference in QALY |
ICER |
|---|---|---|---|
| Base case | −3,767 | 0.070 | PTNS + SNS dominates |
| Probability of >50% improvement in FI for PTNS | |||
| base case 0.59 | |||
| lower limit: 0.59 | −3,767 | 0.070 | PTNS + SNS dominates |
| upper limit:0.71 | −4,968 | 0.087 | PTNS + SNS dominates |
| Probability of receiving permanent SNS | |||
| base case 0.77 | |||
| lower limit: 0.4 | −662 | 0.135 | PTNS + SNS dominates |
| upper limit: 1.0 | −5,697 | 0.029 | PTNS + SNS dominates |
| Probability of >50% improvement in FI for permanent SNS | |||
| base case 0.79 | |||
| lower limit 0.69 | −3,725 | 0.087 | PTNS + SNS dominates |
| upper limit 0.83 | −3,784 | 0.063 | PTNS + SNS dominates |
| Probability of proceeding to SNS after failing PTNS | |||
| base case 0.96 | |||
| lower limit 0.50 | −6,078 | 0.031 | PTNS + SNS dominates |
| upper limit 1.0 | −3,566 | 0.073 | PTNS + SNS dominates |
| Overall probability of adverse events for temporary SNS | |||
| base case 0.22 | |||
| lower limit: 0.02 | −3,809 | 0.069 | PTNS + SNS dominates |
| upper limit: 0.35 | −3,739 | 0.070 | PTNS + SNS dominates |
| Overall probability of adverse events for permanent SNS | |||
| base case 0.24 | |||
| lower limit: 0.13 | −3,553 | 0.069 | PTNS + SNS dominates |
| upper limit: 0.38 | −4,039 | 0.070 | PTNS + SNS dominates |
| Utility for adverse events | |||
| base case 0.46 | |||
| lower limit: 0.16 | −3,767 | 0.068 | PTNS + SNS dominates |
| upper limit: 0.67 | −3,767 | 0.071 | PTNS + SNS dominates |
| Duration of adverse events | |||
| base case 7 days | |||
| lower limit: 3 days | −3,767 | 0.069 | PTNS + SNS dominates |
| upper limit: 14 days | −3,767 | 0.072 | PTNS + SNS dominates |
| Cost of temporary SNS procedure | |||
| base case £599 | |||
| lower limit: £338 | −3,554 | 0.070 | PTNS + SNS dominates |
| upper limit: £710 | −3,861 | 0.070 | PTNS + SNS dominates |
| Cost of permanent SNS procedure | |||
| base case £4,280 | |||
| lower limit: £1,373 | −2,209 | 0.070 | PTNS + SNS dominates |
| upper limit: £5,627 | −4,498 | 0.070 | PTNS + SNS dominates |
| Cost of PTNS procedure | |||
| base case £99 | |||
| lower limit: £53 | −4,876 | 0.070 | PTNS + SNS dominates |
| upper limit: £111 | −3,477 | 0.070 | PTNS + SNS dominates |
| Discounting rate | |||
| base case 3.5% | |||
| lower limit: 1.5% | −3,697 | 0.074 | PTNS + SNS dominates |
| upper limit: 6.0% | −3,845 | 0.065 | PTNS + SNS dominates |
ICER, incremental cost-effectiveness ratio; PTNS, percutaneous tibial nerve stimulation; QALY, quality-adjusted life-year; SNS, sacral nerve stimulation.